Literature DB >> 12710018

Cholinergic nicotinic receptors: competitive ligands, allosteric modulators, and their potential applications.

M Novella Romanelli1, Fulvio Gualtieri.   

Abstract

Discovery of the important role played by nicotinic acetylcholine receptors (nAChRs) in several CNS disorders has called attention to these membrane proteins and to ligands able to modulate their functions. The existence of different subtypes at multiple levels has complicated the understanding of this receptor's physiological role, but at the same time has increased the efforts to discover selective compounds in order to improve the pharmacological characterization of this kind of receptor and to make the possible therapeutical use of its modulators safer. This review focuses on the structure of new ligands for nAChRs, agonists, antagonists and allosteric modulators, and on their possible applications. Copyright 2003 Wiley Periodicals, Inc. Med Res Rev, 23, No. 4, 393-426, 2003

Mesh:

Substances:

Year:  2003        PMID: 12710018     DOI: 10.1002/med.10037

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  22 in total

1.  Subtype-specific actions of beta-amyloid peptides on recombinant human neuronal nicotinic acetylcholine receptors (alpha7, alpha4beta2, alpha3beta4) expressed in Xenopus laevis oocytes.

Authors:  Luanda Pym; Mark Kemp; Valérie Raymond-Delpech; Steven Buckingham; C A R Boyd; David Sattelle
Journal:  Br J Pharmacol       Date:  2005-12       Impact factor: 8.739

2.  Acetylcholine nicotinic receptors: finding the putative binding site of allosteric modulators using the "blind docking" approach.

Authors:  Bogdan Iorga; Denyse Herlem; Elvina Barré; Catherine Guillou
Journal:  J Mol Model       Date:  2005-12-22       Impact factor: 1.810

3.  In vivo effects of the anatoxin-a on striatal dopamine release.

Authors:  F Campos; R Durán; L Vidal; L R F Faro; M Alfonso
Journal:  Neurochem Res       Date:  2006-05-09       Impact factor: 3.996

4.  The α6 nicotinic acetylcholine receptor subunit influences ethanol-induced sedation.

Authors:  Helen M Kamens; Nicole R Hoft; Ryan J Cox; Jill H Miyamoto; Marissa A Ehringer
Journal:  Alcohol       Date:  2012-05-07       Impact factor: 2.405

5.  Estimating binding affinities of the nicotinic receptor for low-efficacy ligands using mixtures of agonists and two-dimensional concentration-response relationships.

Authors:  Yamini Purohit; Claudio Grosman
Journal:  J Gen Physiol       Date:  2006-06       Impact factor: 4.086

6.  Nicotinic α4β2 receptor imaging agents. Part IV. Synthesis and biological evaluation of 3-(2-(S)-3,4-dehydropyrrolinyl methoxy)-5-(3'-¹⁸F-fluoropropyl)pyridine (¹⁸F-Nifrolene) using PET.

Authors:  Rama Pichika; Sharon A Kuruvilla; Narmisha Patel; Kenny Vu; Sangamitra Sinha; Balu Easwaramoorthy; Tanjore K Narayanan; Bingzhi Shi; Bradley Christian; Jogeshwar Mukherjee
Journal:  Nucl Med Biol       Date:  2012-11-07       Impact factor: 2.408

7.  The nicotinic acetylcholine receptor gene family of the honey bee, Apis mellifera.

Authors:  Andrew K Jones; Valerie Raymond-Delpech; Steeve H Thany; Monique Gauthier; David B Sattelle
Journal:  Genome Res       Date:  2006-10-25       Impact factor: 9.043

Review 8.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

9.  Computational neural network analysis of the affinity of N-n-alkylnicotinium salts for the alpha4beta2* nicotinic acetylcholine receptor.

Authors:  Fang Zheng; Guangrong Zheng; A Gabriela Deaciuc; Chang-Guo Zhan; Linda P Dwoskin; Peter A Crooks
Journal:  J Enzyme Inhib Med Chem       Date:  2009-02       Impact factor: 5.051

10.  Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats.

Authors:  Krista Spiller; Zheng-Xiong Xi; Xia Li; Charles R Ashby; Patrick M Callahan; Ashok Tehim; Eliot L Gardner
Journal:  Neuropharmacology       Date:  2009-04-22       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.